We are live on ! Find out more
GTBP icon

GT Biopharma

11 hedge funds and large institutions have $38.1M invested in GT Biopharma in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,500% more capital inflows, than outflows

Capital inflows: $3.63M | Capital outflows: $37.8K

44.54% more ownership

Funds ownership: 5.47% → 50.01% (+45%)

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

GTBP Hedge Fund Activity: Q2 2024 in Review

11 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2024, worth a combined $38.1M — up 10,838% from $349K a quarter earlier.

Fund positioning in GTBP was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 3 trimmed.

The largest buyer was DekaBank Deutsche Girozentrale, opening a new position worth an estimated $3.5M. The largest seller was Vanguard Group, cutting an estimated $35.8K.

  • 11 institutional investors held GT Biopharma (GTBP) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $38.1M of GT Biopharma stock for Q2 2024, up 10,838% quarter-over-quarter.
  • 2 funds opened new GT Biopharma positions in Q2 2024 and 2 closed out, a net change of 0 holders.
  • The largest GT Biopharma buyer in Q2 2024 was DekaBank Deutsche Girozentrale, an estimated $3.5M added.
  • The largest GT Biopharma seller in Q2 2024 was Vanguard Group, an estimated $35.8K sold.

Based on aggregated 13F filings for Q2 2024.